Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

View correction statement:

Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate–severe Gram-positive infections [Corrigendum]

This article refers to:

Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus

Tavares RCF, Feldner AC, Pinho JR, et al. Infect Drug Resist. 2018;11:1993–2000.

Page 1999, reference 40 was listed incorrectly. “Alves da Silva R. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.” should read “Alves da Silva R, Todão JS, Kamitani FL, et al. Molecular characterization of hepatitis C virus in end-stage renal disease patients under hemodialysis. Journal of Medical Virology 90. 2018;3:537–544.”